Statement Of Financial Position [Abstract]

Innate Pharma - Filing #858132

Concept	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment	8 542 EUR	—	—	—	—	—	—	—	—	—	—	10 174 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intangible assets other than goodwill	1 556 EUR	—	—	—	—	—	—	—	—	—	—	44 192 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Deferred tax assets	8 568 EUR	—	—	—	—	—	—	—	—	—	—	5 028 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Trade and other receivables	52 445 EUR	—	—	—	—	—	—	—	—	—	—	48 241 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	51 635 EUR
Cash and cash equivalents	84 225 EUR	—	—	—	—	—	—	—	—	—	—	103 756 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	136 792 EUR
Assets	207 863 EUR	—	—	—	—	—	—	—	—	—	—	267 496 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	4 011 EUR	—	—	—	—	—	—	—	—	—	—	3 978 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Share premium	379 637 EUR	—	—	—	—	—	—	—	—	—	—	375 220 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other reserves	819,000 EUR	—	—	—	—	—	—	—	—	—	—	456,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity	54 151 EUR	58 103 EUR	819,000 EUR	379 637 EUR	272 213 EUR	4 011 EUR	219 404 EUR	— EUR	456,000 EUR	— EUR	1 054 EUR	107 440 EUR	1 054 EUR	52 809 EUR	— EUR	— EUR	— EUR	— EUR	375 220 EUR	3 978 EUR	156 476 EUR	63 984 EUR	3 950 EUR	355,000 EUR	372 131 EUR	155 976 EUR
Liabilities [abstract]
Trade and other payables	20 911 EUR	—	—	—	—	—	—	—	—	—	—	28 573 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	29 519 EUR
Deferred tax liabilities	8 568 EUR	—	—	—	—	—	—	—	—	—	—	5 028 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities	207 863 EUR	—	—	—	—	—	—	—	—	—	—	267 496 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—